Status: Recruiting
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19/BCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases.
Participants needed: 8
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd.Updated: Aug 27, 2025Locations: 1
Eligibility criteria
1) Has provided signed informed consent; 2) Is aged 18-65 years ; 3)Adequate fun...
1) Requires dialysis treatment. 2) History of severe drug hypersensitivity. 3) A...